Early on-treatment weight loss was not associated with progression-free survival or time to discontinuation of enfortumab vedotin. Early weight loss after the start of first-line treatment with ...
The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...
Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses on three key areas of ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. David Cade presented LUTEON, an ongoing phase III trial ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Background More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 ...
Jelmyto shows long-term effectiveness in treating low-grade, upper tract urothelial carcinoma, with a high complete response rate in the OLYMPUS trial. The median duration of response for patients ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results